CRIS Current Research Information System

BACCARANI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.797
EU - Europa 19.710
AS - Asia 18.026
AF - Africa 1.373
SA - Sud America 1.201
Continente sconosciuto - Info sul continente non disponibili 74
OC - Oceania 26
Totale 68.207
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.592
GB - Regno Unito 5.876
CN - Cina 5.456
SG - Singapore 5.260
VN - Vietnam 3.588
SE - Svezia 3.102
DE - Germania 2.478
IT - Italia 2.275
HK - Hong Kong 1.311
RU - Federazione Russa 1.114
IN - India 1.097
UA - Ucraina 1.036
BR - Brasile 865
FR - Francia 845
IE - Irlanda 717
NL - Olanda 600
ZA - Sudafrica 444
JP - Giappone 392
EE - Estonia 391
TG - Togo 370
CH - Svizzera 266
KR - Corea 252
FI - Finlandia 248
CI - Costa d'Avorio 216
JO - Giordania 200
BG - Bulgaria 172
AR - Argentina 163
SC - Seychelles 140
CA - Canada 130
NG - Nigeria 128
BE - Belgio 121
IR - Iran 99
GR - Grecia 87
PL - Polonia 80
AT - Austria 75
HR - Croazia 74
TR - Turchia 73
EU - Europa 66
EC - Ecuador 63
ID - Indonesia 60
BD - Bangladesh 51
MX - Messico 51
ES - Italia 40
LB - Libano 34
MY - Malesia 30
CL - Cile 28
RO - Romania 27
PY - Paraguay 25
CO - Colombia 24
UZ - Uzbekistan 23
CZ - Repubblica Ceca 21
AU - Australia 19
IQ - Iraq 13
MA - Marocco 13
VE - Venezuela 13
LT - Lituania 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
IL - Israele 11
SA - Arabia Saudita 10
EG - Egitto 9
KE - Kenya 9
PE - Perù 9
DZ - Algeria 8
PH - Filippine 8
RS - Serbia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AL - Albania 6
PK - Pakistan 6
PT - Portogallo 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
NO - Norvegia 5
QA - Qatar 5
TH - Thailandia 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
CR - Costa Rica 4
NP - Nepal 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
BY - Bielorussia 3
GT - Guatemala 3
HN - Honduras 3
KZ - Kazakistan 3
MK - Macedonia 3
TZ - Tanzania 3
BF - Burkina Faso 2
BS - Bahamas 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GY - Guiana 2
HU - Ungheria 2
LK - Sri Lanka 2
LU - Lussemburgo 2
ML - Mali 2
Totale 68.167
Salva come PNG Salva come JPEG
Città #
Southend 5.272
Fairfield 3.338
Singapore 3.266
Ashburn 2.678
Chandler 2.417
Woodbridge 1.753
Houston 1.569
Seattle 1.564
Wilmington 1.536
Dong Ket 1.340
Hong Kong 1.294
Cambridge 1.206
Ann Arbor 1.200
Princeton 1.073
Beijing 916
Santa Clara 836
Dublin 712
Hefei 673
Boardman 661
Jacksonville 632
Nanjing 532
Ho Chi Minh City 490
Westminster 470
Padova 462
Lomé 369
Tokyo 329
Los Angeles 326
Hanoi 323
Bologna 316
New York 290
Berlin 269
Jinan 249
Saint Petersburg 237
Seoul 236
Buffalo 229
Shenyang 222
Dallas 219
Abidjan 215
Bern 215
Helsinki 215
Amman 200
San Diego 198
Turin 197
Milan 185
Sofia 170
Bremen 166
Hebei 166
Changsha 161
Nanchang 160
Medford 133
Redondo Beach 131
Jiaxing 117
Brussels 112
Munich 112
Mülheim 111
Tianjin 110
Redmond 107
Abeokuta 105
Zhengzhou 105
Frankfurt am Main 103
Florence 102
Redwood City 98
Guangzhou 97
São Paulo 97
Falls Church 87
Norwalk 80
Haikou 76
Hangzhou 72
Mahé 72
Shanghai 69
Rome 66
Des Moines 65
Dearborn 64
London 62
Falkenstein 59
Ningbo 58
Toronto 57
Taizhou 56
Bengaluru 54
Taiyuan 54
Yubileyny 51
Haiphong 50
Phoenix 50
Verona 49
Chicago 48
Da Nang 48
Olalla 48
Warsaw 46
Istanbul 42
Lanzhou 41
Kunming 39
Wuhan 39
Nuremberg 36
San Francisco 35
Vienna 35
Bühl 34
Mountain View 34
Andover 33
Biên Hòa 33
Orem 33
Totale 45.267
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 362
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 316
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 313
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 309
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 297
18F-FDG PET early after radiotherapy in lymphoma patients. 291
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 285
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 280
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 269
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 267
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 262
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 260
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 255
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 255
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 251
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 240
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 239
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 237
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 234
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 232
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 230
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 229
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 228
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 225
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 225
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 224
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 220
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 220
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 218
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 215
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 215
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 212
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 210
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 207
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 206
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 206
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 206
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 204
Advances in the treatment for haematological malignancies. 203
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 203
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 200
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 199
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 198
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 197
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 197
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 197
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 197
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 196
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 196
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 195
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 195
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 194
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 194
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 194
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 194
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 194
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 193
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 193
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 192
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 191
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 189
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 189
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 189
Immune therapy of chronic myelogenous leukemia. 188
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 188
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 187
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 187
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 187
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 185
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 184
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 183
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 182
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 181
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 179
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 179
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 178
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 178
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 178
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 178
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 178
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 177
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 176
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 176
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 176
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 175
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. 175
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 175
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 175
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 175
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 174
Analisi di polimorfismi in geni coinvolti nel ciclo dei folati come determinanti di suscettibilità a leucemia mieloide cronica. 174
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 173
Monitoring treatment of chronic myeloid leukemia. 172
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 172
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 172
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 172
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 172
Totale 20.874
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.760
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.124 0 0 0 0 0 421 172 436 714 432 467 2.482
2021/20229.676 1.049 266 732 966 913 622 191 620 358 759 1.637 1.563
2022/202310.230 1.238 1.565 583 1.336 673 816 370 532 1.615 235 808 459
2023/20242.524 151 423 151 247 208 599 152 134 87 153 97 122
2024/20259.165 274 1.609 770 686 1.459 482 760 192 66 811 236 1.820
2025/202610.306 1.394 2.172 2.131 1.383 2.534 692 0 0 0 0 0 0
Totale 69.381